Compared with DPP-4 inhibitors, GLP-1 RAs exhibit superior efficacy in cardiovascular protection, with GLP-1 metabolites contributing to improved functional recovery and cardiomyocyte viability following ischemia/reperfusion injury. The gene discussed is GLP1R; the disease is ischemia.